Worlds First Intranasal Covid Vaccine From Bharat Biotech Gets Approval, No Efficacy Data Released
Needle Free! India Gets First Intranasal Vaccine Against COVID-19; All You Need To Know
Why Is Bharat Biotech Repeatedly Justifying Covaxins Efficacy?
After Graft Row, Bharat Biotech Suspends Brazil Covaxin Deal
Brazil Cancels $324 Million Covaxin Deal With Bharat Biotech
Covaxin Phase 3 Trials Show 77.8% Efficacy Against COVID-19
Claim Of Newborn Calf Serum In Covaxin Is False, BJP Accuses Congress Of Spreading Misinformation
Vacillating Between Virus And Vaccines: Intricacies Of Achieving Mass Inoculation
Nine Hospitals Procure 50% COVID Vaccine, Raise Concerns Of Uneven Distribution
Bharat Biotech Wants To Have Maximum Possible Price For Covaxin To Reinvest The Money Into R&D
Drug Regulator Panel Recommends Phase I Trial For Bharat Biotechs Intranasal COVID-19 Vaccine
Health Ministry Refuses To Furnish Data Used For Approval Of COVID Vaccines Under RTI